CD39 Antibody (BU61): sc-65262

CD39 Antibody (BU61) is a mouse monoclonal IgG1 kappa light chain antibody that detects CD39 protein of human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and flow cytometry (FCM). Anti-CD39 antibody (BU61) is available as the non-conjugated isotype antibody. CD39, also known as ectonucleoside triphosphate diphosphohydrolase 1 (ENP1), is an integral membrane glycoprotein that plays a crucial role in regulating extracellular nucleotide levels by hydrolyzing ATP and ADP to AMP, which is vital for maintaining vascular homeostasis and preventing excessive platelet aggregation. The enzymatic activity of CD39 is particularly important in the context of thrombosis, as CD39 helps to modulate the balance between pro- and anti-thrombotic signals in the bloodstream. Additionally, CD39 is subject to post-translational modifications, including glycosylation at six N-glycosylation sites, which are essential for proper folding, stability, and function. This glycosylation not only influences enzymatic activity but also localization to the cell membrane, where CD39 exerts its effects. CD39 is expressed in various tissues, including vascular tissues such as the placenta, lung, skeletal muscle, and kidney, as well as in immune cells like activated B cells, natural killer cells, macrophages, dendritic cells, and platelets. Given its significant role in modulating immune responses and preventing thrombosis, CD39 is being explored as a potential therapeutic target for conditions such as coronary artery occlusion and thrombotic stroke.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CD39 Antibody (BU61) References:

1. Mammalian plasma membrane ecto-nucleoside triphosphate diphosphohydrolase 1, CD39, is not active intracellularly. The N-glycosylation state of CD39 correlates with surface activity and localization.  |  Zhong, X., et al. 2001. J Biol Chem. 276: 41518-25. PMID: 11546800
2. Inhibition of platelet recruitment by endothelial cell CD39/ecto-ADPase: significance for occlusive vascular diseases.  |  Marcus, AJ., et al. 2001. Ital Heart J. 2: 824-30. PMID: 11770867
3. Localization of NTPDase1/CD39 in normal and transformed human pancreas.  |  Kittel, A., et al. 2002. J Histochem Cytochem. 50: 549-56. PMID: 11897808
4. Expression, distribution, and biochemistry of human CD39. Role in activation-associated homotypic adhesion of lymphocytes.  |  Kansas, GS., et al. 1991. J Immunol. 146: 2235-44. PMID: 1672348
5. CD39 and CD73 in immunity and inflammation.  |  Antonioli, L., et al. 2013. Trends Mol Med. 19: 355-67. PMID: 23601906
6. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors.  |  Duhen, T., et al. 2018. Nat Commun. 9: 2724. PMID: 30006565
7. CD39 Regulation and Functions in T Cells.  |  Timperi, E. and Barnaba, V. 2021. Int J Mol Sci. 22: PMID: 34360833
8. CD73 Inhibits cGAS-STING and Cooperates with CD39 to Promote Pancreatic Cancer.  |  Jacoberger-Foissac, C., et al. 2023. Cancer Immunol Res. 11: 56-71. PMID: 36409930
9. The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancer.  |  Chow, A., et al. 2023. Immunity. 56: 93-106.e6. PMID: 36574773
10. CD39/CD73/A2AR pathway and cancer immunotherapy.  |  Xia, C., et al. 2023. Mol Cancer. 22: 44. PMID: 36859386
11. CD39 inhibition and VISTA blockade may overcome radiotherapy resistance by targeting exhausted CD8+ T cells and immunosuppressive myeloid cells.  |  Zhang, Y., et al. 2023. Cell Rep Med. 4: 101151. PMID: 37567173
12. Identification and characterization of CD39/vascular ATP diphosphohydrolase.  |  Kaczmarek, E., et al. 1996. J Biol Chem. 271: 33116-22. PMID: 8955160

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-CD39 Antibody (BU61) has 3 citations in a variety of scientific publications.

Primary antibodies like Anti-CD39 Antibody (BU61) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

CD39 Antibody (BU61) Specifications

Alternate Product Name: CD39

Product Clone Name: BU61

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids:

Epitope Target: CD39

Epitope Species: human

Product Reactivity/Detection: CD39

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, FCM

Vialing Information: Each vial contains 100 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 3 citations in various scientific publications

Available Conjugates/Forms for CD39 Antibody (BU61): N/A